Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial.
Hyung Jun ParkYong Man KimJae Seob JungWonjun JiJae Cheol LeeChang-Min ChoiPublished in: Thoracic cancer (2022)
Autologous NK cells can enhance the long-term OS and PFS for NSCLC. A larger study is needed to confirm this result. Clinical Research Information Service number: KCT0003463.